[CLASSIFIED // EYES ONLY]

Kevin Sobieski, the CEO of a tiny biotech firm with no FDA-approved products, just secured a $500 million government contract to 'fast-track' an experimental diabetes drug—while his company's board is stacked with former regulators who helped draft the approval guidelines.